HMGB1 increases RAGE expression in vascular smooth muscle cells via ERK and p-38 MAPK-dependent pathways

The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given t...

Full description

Saved in:
Bibliographic Details
Published inThe Korean journal of physiology & pharmacology Vol. 26; no. 5; pp. 389 - 396
Main Authors Jang, Eun Jeong, Kim, Heejeong, Baek, Seung Eun, Jeon, Eun Yeong, Kim, Ji Won, Kim, Ju Yeon, Kim, Chi Dae
Format Journal Article
LanguageEnglish
Published The Korean Physiological Society and The Korean Society of Pharmacology 01.09.2022
대한약리학회
Subjects
Online AccessGet full text
ISSN1226-4512
2093-3827
DOI10.4196/kjpp.2022.26.5.389

Cover

Abstract The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)-induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPK-RAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures.The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)-induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPK-RAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures.
AbstractList The increased expression of receptors for advanced glycation endproduct (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)- induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPKRAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures. KCI Citation Count: 0
The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)-induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPK-RAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures.The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)-induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPK-RAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures.
The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)-induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPK-RAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures.
Author Jeon, Eun Yeong
Kim, Ji Won
Jang, Eun Jeong
Baek, Seung Eun
Kim, Ju Yeon
Kim, Heejeong
Kim, Chi Dae
AuthorAffiliation 1 Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea
3 Department of Anatomy, School of Medicine, Pusan National University, Yangsan 50612, Korea
2 Department of Laboratory Medicine, Pusan National University Hospital, Busan 49241, Korea
AuthorAffiliation_xml – name: 3 Department of Anatomy, School of Medicine, Pusan National University, Yangsan 50612, Korea
– name: 1 Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea
– name: 2 Department of Laboratory Medicine, Pusan National University Hospital, Busan 49241, Korea
Author_xml – sequence: 1
  givenname: Eun Jeong
  surname: Jang
  fullname: Jang, Eun Jeong
  organization: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea
– sequence: 2
  givenname: Heejeong
  surname: Kim
  fullname: Kim, Heejeong
  organization: Department of Laboratory Medicine, Pusan National University Hospital, Busan 49241, Korea
– sequence: 3
  givenname: Seung Eun
  surname: Baek
  fullname: Baek, Seung Eun
  organization: Department of Anatomy, School of Medicine, Pusan National University, Yangsan 50612, Korea
– sequence: 4
  givenname: Eun Yeong
  surname: Jeon
  fullname: Jeon, Eun Yeong
  organization: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea
– sequence: 5
  givenname: Ji Won
  surname: Kim
  fullname: Kim, Ji Won
  organization: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea
– sequence: 6
  givenname: Ju Yeon
  surname: Kim
  fullname: Kim, Ju Yeon
  organization: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea
– sequence: 7
  givenname: Chi Dae
  surname: Kim
  fullname: Kim, Chi Dae
  organization: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea
BackLink https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002873479$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9UctO3DAUtRAVTCk_wMrLqlKCH4ljbypN0XRAgFqNYG15nJuOO4mT2slQ_r4eBhbtoqu7OI97dM57dOx7DwhdUJIXVInL7c9hyBlhLGciL3Mu1RGaMaJ4xiWrjtGMMiayoqTsFJ3H6NaEyJKUkqgTdMoF4ariaoY21_fLLxQ7bwOYCBGv5ssFht9DgCTqfULwzkQ7tSbg2PX9uMHdFG0L2ELbRrxzBi9Wt9j4Gg_pN76ff7_NahjA1-BHPJhx82Se4wf0rjFthPPXe4Yevy4erq6zu2_Lm6v5XWYLWoyZIaypioZxZSoBDVGVKhtOFOVUWisJCFNzCoRJUYt1YYWA2jAlJBcFUGj4Gfp08PWh0VvrdG_cy_3R623Q89XDjaaEpL4KmcifD-RhWndQ2xQ4mFYPwXUmPL9I_0a82ySjnVYFr7ioksHHV4PQ_5ogjrpzcV-M8dBPUbOKSCaopCpR5YFqQx9jgEZbN5oxdZycXZtC6f2wej-s3g-rmdClTkGTlP0jfUv4H9Efp7aneg
CitedBy_id crossref_primary_10_4196_kjpp_2024_28_5_449
crossref_primary_10_4196_kjpp_2024_28_6_503
crossref_primary_10_1007_s11010_024_05132_8
crossref_primary_10_3390_nu14194047
crossref_primary_10_58502_DTT_24_0009
crossref_primary_10_1093_cvr_cvad189
crossref_primary_10_4196_kjpp_24_220
crossref_primary_10_2147_DMSO_S496360
Cites_doi 10.1161/01.CIR.103.24.2980
10.1038/382685a0
10.1002/jcb.25682
10.4103/2319-4170.117622
10.1189/jlb.0908548
10.1182/blood.V87.6.2095.bloodjournal8762095
10.1038/emm.2006.62
10.1038/onc.2012.631
10.1016/j.cardiores.2005.05.004
10.14670/HH-29.235
10.1016/j.bbamcr.2008.11.016
10.1016/j.vph.2019.04.001
10.1016/j.cardiores.2005.08.002
10.1007/s11010-015-2396-0
10.1161/01.ATV.0000145573.36113.8a
10.1371/journal.pone.0128881
10.1016/S1043-2760(00)00311-8
10.1096/fj.06-5867fje
10.1111/ajt.12781
10.1016/j.intimp.2005.05.003
10.1155/2015/354517
10.1007/s00125-009-1458-9
10.1161/ATVBAHA.107.159327
10.1146/annurev-immunol-030409-101323
10.1172/JCI200114002
10.1080/15384101.2015.1100771
10.1161/01.ATV.0000131783.74034.97
ContentType Journal Article
Copyright Copyright © Korean J Physiol Pharmacol 2022
Copyright_xml – notice: Copyright © Korean J Physiol Pharmacol 2022
DBID AAYXX
CITATION
7X8
5PM
ACYCR
DOI 10.4196/kjpp.2022.26.5.389
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2093-3827
EndPage 396
ExternalDocumentID oai_kci_go_kr_ARTI_10038948
PMC9437367
10_4196_kjpp_2022_26_5_389
GroupedDBID ---
5-W
5GY
8JR
8XY
9ZL
AAYXX
ABDBF
ACUHS
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
ESX
F5P
GX1
HYE
MK0
OK1
P2P
P5Y
P6G
RPM
TR2
TUS
7X8
5PM
.UV
53G
ABPTK
ACYCR
KVFHK
ID FETCH-LOGICAL-c414t-a02f74f239a76ef09795f3091318cc80e6ad31e0286d6b4c66eda2968364e1ef3
ISSN 1226-4512
IngestDate Tue Nov 21 21:39:56 EST 2023
Thu Aug 21 18:11:09 EDT 2025
Fri Jul 11 08:15:07 EDT 2025
Tue Jul 01 02:33:17 EDT 2025
Thu Apr 24 23:02:26 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c414t-a02f74f239a76ef09795f3091318cc80e6ad31e0286d6b4c66eda2968364e1ef3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: E.J.J. and C.D.K. designed the study. S.E.B., E.Y.J., J.W.K., and J.Y.K. performed the experiments. H.K. and C.D.K. wrote the manuscript.
These authors contributed equally to this work.
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC9437367
PMID 36039739
PQID 2708261819
PQPubID 23479
PageCount 8
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_10038948
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9437367
proquest_miscellaneous_2708261819
crossref_citationtrail_10_4196_kjpp_2022_26_5_389
crossref_primary_10_4196_kjpp_2022_26_5_389
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-01
20220901
2022-09
PublicationDateYYYYMMDD 2022-09-01
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-01
  day: 01
PublicationDecade 2020
PublicationTitle The Korean journal of physiology & pharmacology
PublicationYear 2022
Publisher The Korean Physiological Society and The Korean Society of Pharmacology
대한약리학회
Publisher_xml – name: The Korean Physiological Society and The Korean Society of Pharmacology
– name: 대한약리학회
References ref13
ref12
ref15
ref14
ref11
ref10
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref27
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref25
  doi: 10.1161/01.CIR.103.24.2980
– ident: ref12
  doi: 10.1038/382685a0
– ident: ref6
  doi: 10.1002/jcb.25682
– ident: ref1
  doi: 10.4103/2319-4170.117622
– ident: ref2
  doi: 10.1189/jlb.0908548
– ident: ref17
  doi: 10.1182/blood.V87.6.2095.bloodjournal8762095
– ident: ref26
  doi: 10.1038/emm.2006.62
– ident: ref8
  doi: 10.1038/onc.2012.631
– ident: ref18
  doi: 10.1016/j.cardiores.2005.05.004
– ident: ref24
  doi: 10.14670/HH-29.235
– ident: ref11
  doi: 10.1016/j.bbamcr.2008.11.016
– ident: ref10
  doi: 10.1016/j.vph.2019.04.001
– ident: ref14
  doi: 10.1016/j.cardiores.2005.08.002
– ident: ref27
  doi: 10.1007/s11010-015-2396-0
– ident: ref3
  doi: 10.1161/01.ATV.0000145573.36113.8a
– ident: ref21
  doi: 10.1371/journal.pone.0128881
– ident: ref22
  doi: 10.1016/S1043-2760(00)00311-8
– ident: ref7
  doi: 10.1096/fj.06-5867fje
– ident: ref5
  doi: 10.1111/ajt.12781
– ident: ref15
  doi: 10.1016/j.intimp.2005.05.003
– ident: ref19
  doi: 10.1155/2015/354517
– ident: ref13
  doi: 10.1007/s00125-009-1458-9
– ident: ref16
  doi: 10.1161/ATVBAHA.107.159327
– ident: ref9
  doi: 10.1146/annurev-immunol-030409-101323
– ident: ref23
  doi: 10.1172/JCI200114002
– ident: ref4
  doi: 10.1080/15384101.2015.1100771
– ident: ref20
  doi: 10.1161/01.ATV.0000131783.74034.97
SSID ssib008505809
ssj0064464
Score 2.2916236
Snippet The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However,...
The increased expression of receptors for advanced glycation endproduct (RAGE) is known as a key player in the progression of vascular remodeling. However, the...
SourceID nrf
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 389
SubjectTerms Original
약리학
Title HMGB1 increases RAGE expression in vascular smooth muscle cells via ERK and p-38 MAPK-dependent pathways
URI https://www.proquest.com/docview/2708261819
https://pubmed.ncbi.nlm.nih.gov/PMC9437367
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002873479
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX The Korean Journal of Physiology & Pharmacology, 2022, 26(5), , pp.389-396
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGLW2ISFeEDAQ4yYjCC9RSmI7jv2YXthgGpqmTdpblKTOVsbSqmmB8ev5bCdpM6Zp8BJZsWO7OSfJsfv5GKH3nLOsUPAgZSEJPUZV6IGqJl6e-TKP8kD4Qq93PvjK907Yl9PwdGPz_lrU0nKR9fLfN64r-R9U4RzgqlfJ_gOybaVwAtKALxwBYTjeCeO9g91-4E5KrfwqVblH-u8h9auObTUxjG2kaXU5BVDcy2UFlbh6vr5yf0xSd3S0b80CPCrcg_hw32v2xV1o09Xzn-lVta5gNa_2p_NmAr8Ws2aCxNo5aS7NVobY7ZS9Mxo4cuTEoUkMdYgFJGLfsdtf2iKx05cmZ6iLxIMbivSdvu_0A50jTPGmuvWG4BrBOg1J4dhdW5o5DhgeN0FclpW6ajFoWg8daVqHRH-os2Ju-mOzpEnEUH7trQ4a02NhHa-tzDniSwo31hoT1G9vanczqoUAtVvtXv_GMHhnATEuvs203SkhPcJ7Ya-9dN3Q-9qHtmPpfZFPkrNpcjFPYODyWVtHQxVMbKJ7JIpMwMHu6erNK0CoGqM1qzFAxBpjtPaH2eVgumsf_-5YR3JtlvOiM5rqxgKviavjR-hhPSrCsaX4Y7ShyidoOy7TxfTyCn_Ahy29ttG5YT1uWY816_GK9ZCDG9Zjy3psWY8N6zGwHgPrMbAea9bjLutxw_qn6OTT6Hiw59X7hXg5C9jCS31SRKwgVKYRV4UvIxkWVBvfBiLPha94OqaBAkXNxzxjOedqnBLJBeVMBaqgz9BWOS3Vc4QJHQvBhQp4RBnPmYBhCwlzPxCcqkwWOyhobmmS12b6ek-X7wBkomFINAyJhiEhPAkTgGEHue01M2slc2vpd4CUocktdNlBbxskE_gu6NuYlmq6rBISgbjnoN-hpqgDcdu4rrebU07OjcO81IZnPHpxpz68RA9Wz-wrtLWYL9VrUOqL7I0h8R9UG9F0
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HMGB1+increases+RAGE+expression+in+vascular+smooth+muscle+cells+via+ERK+and+p-38+MAPK-dependent+pathways&rft.jtitle=The+Korean+journal+of+physiology+%26+pharmacology&rft.au=%EC%9E%A5%EC%9D%80%EC%A0%95&rft.au=%EA%B9%80%ED%9D%AC%EC%A0%95&rft.au=%EB%B0%B1%EC%8A%B9%EC%9D%80&rft.au=%EC%A0%84%EC%9D%80%EC%98%81&rft.date=2022-09-01&rft.pub=%EB%8C%80%ED%95%9C%EC%95%BD%EB%A6%AC%ED%95%99%ED%9A%8C&rft.issn=1226-4512&rft.eissn=2093-3827&rft.spage=389&rft.epage=396&rft_id=info:doi/10.4196%2Fkjpp.2022.26.5.389&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_10038948
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1226-4512&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1226-4512&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1226-4512&client=summon